Affymetrix Expands the Expression Power of the GeneAtlas® Personal Microarray System
14 June 2011 - 8:15PM
Business Wire
Affymetrix, Inc. (NASDAQ:AFFX) today announced the availability
of the most widely cited gene expression microarray for use on the
GeneAtlas® Personal Microarray System, bringing the power of the
world’s largest collection of referenced microarray gene expression
data to the personal bench-top of every life scientist. The new
array strip format for the GeneChip® Human Genome (HG)-U133 Array
combined with the easy workflow of the GeneAtlas System gives
researchers a cost-effective solution for in-house whole-genome
expression analysis.
Proven performance from the industry
standard The Affymetrix(R) Human Genome U133+ PM Array Strip
enables expression profiling of four samples at a time using the
same content as the GeneChip(R) HT HG-U133+ PM Array Plate, which
is based on the industry-standard GeneChip(R) Human Genome U133
Plus 2.0 Array.* (Photo: Business Wire)
The new HG-U133+ PM Array Strip leverages the knowledge
accumulated from multiple sources, including UniGene, RefSeq, the
National Center for Biotechnology information (NCBI), and GenBank®
to provide the most comprehensive view of the transcribed genome.
Using more than 500,000 probes for independent measurements of gene
expression per sample and as many as 9 to 11 unique probes to
interrogate every mRNA transcript, the HG-U133+ PM Array Strip
delivers a high level of sequence coverage and data confidence.
Additionally, the GeneAtlas System’s data analysis solution
automatically translates the new array strip’s differential
expression data into relevant results. It also mines through
thousands of research papers that reference the HG-U133 Array
design for findings that are significant to a gene or gene-network
of interest. Moreover, since Affymetrix routinely updates sequence
files every six months for all of its arrays, researchers are
assured access to the most relevant whole-genome information and
the highest sequence coverage available.
“By designing the most widely cited array for use on the
industry’s first personal microarray analysis system, we are
unlocking important content for a whole new set of scientists who
couldn’t access it before,” said Kevin Cannon, PhD, Vice President
of Marketing for Expression Applications at Affymetrix. “The power
of the HG-U133 Array on the GeneAtlas System unleashes a tremendous
opportunity for discovery,” Dr. Cannon added. “Affymetrix is
enabling life scientists, at every level and in all areas, to
publish more quickly because of the superior performance, high data
confidence, and easy workflow solution that we’re delivering.”
Other array strips available for use on the complete personal
GeneAtlas System for microarray processing include the Affymetrix®
Human Genome U219 Array Strip as well as the Affymetrix® MG-430 PM
Array Strip and Affymetrix® RG-230 PM Array Strip, for mouse and
rat, respectively; and the Affymetrix® Human Gene 1.1 ST Array
Strip, Affymetrix® Mouse Gene 1.1 ST Array Strip, and Affymetrix®
Rat Gene 1.1 ST Array Strip for gene, exon, and alternative
splicing analysis.
Learn more about the power of the new HG-U133+ PM Array Strip on
the GeneAtlas Personal Microarray System.
About Affymetrix
Affymetrix technology is used by the world's top pharmaceutical,
diagnostic, and biotechnology companies, as well as leading
academic, government, and nonprofit research institutes. More than
2,100 systems have been shipped around the world and more than
23,500 peer-reviewed papers have been published using the
technology. Affymetrix is headquartered in Santa Clara, Calif., and
has manufacturing facilities in Santa Clara, Cleveland, Ohio, and
Singapore. The company has about 900 employees worldwide and
maintains sales and distribution operations across Europe, Latin
America, and Asia. For more information about Affymetrix, please
visit http://www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
“forward-looking statements” within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix’ “expectations,” “beliefs,” “hopes,”
“intentions,” “strategies” or the like. Such statements are subject
to risks and uncertainties that could cause actual results to
differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix’ Form 10-K for the
year ended December 31, 2010, and other SEC reports for subsequent
quarterly periods.
NOTE: Affymetrix, the Affymetrix logo, GeneChip, and GeneAtlas,
are trademarks or registered trademarks of Affymetrix, Inc.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6758938&lang=en
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2023 to Aug 2024